We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Patterson Companies (PDCO) Earnings Beat Estimates in Q4
Read MoreHide Full Article
Patterson Companies Inc. (PDCO - Free Report) reported fourth-quarter fiscal 2017 adjusted earnings of 69 cents per share from continuing operations, which outpaced the Zacks Consensus Estimate of 64 cents. The figure, however, came lower than the year-ago quarterly figure of 77 cents.
Net sales from continuing operations dipped 0.62% from the year-ago quarter to $1.45 billion missing the Zacks Consensus Estimate of $1.47 billion.
Stock Performance
The price performance of the stock has been unfavorable over the last three months. Patterson Companies shed 1.24%, comparing unfavorably versus the Zacks classified Medical - Dental Supplies sub-industry’s gain of almost 5.46%.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Coming to the Animal Health platform (58% of total sales), sales increased almost 6.0% on a year-over-year basis to $827.5 million. Sales of Consumable grew 5.1% year over year. However, the Other services and products on this platform witnessed a 5.8% year-over-year decline in sales.
Patterson Companies’ Dental platform (42% of total sales) sales fell 8.3% year over year to $607.3 million approximately. Consumable sales at the Dental platform dropped 4.3% year over year to $339.4 million, while sales from other services and products increased by 0.2%. Sales from dental equipment and software dipped 16.9%.
Financial Condition
Cash and cash equivalents were $94.9 million as of Apr 29, 2017 compared to $137.5 million as of Apr 30, 2016. In fiscal 2017, Patterson repurchased approximately 2.9 million shares for $125.4 million. This leaves approximately 13.6 million shares for repurchase under the current authorization, which expires in Mar 2018. The company also disbursed $25.0 million in cash dividends to shareholders in the fourth quarter and $95.9 million in cash dividends to shareholders in fiscal 2017.
Outlook
Patterson Companies affirmed its adjusted earnings in the range of $2.25–$2.40 per share for fiscal 2018. GAAP earnings are expected to be in the range of $1.90 to $2.05 per diluted share.
Zacks Rank & Key Picks
Patterson Companies currently has a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector are Luminex Corp. , Inogen, Inc. (INGN - Free Report) and Edwards Lifesciences, Inc. (EW - Free Report) . Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock roughly added 7.0% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 82%.
Edwards Lifesciences has an expected long-term adjusted earnings growth of almost 16% (last 3–5 years of actual earnings). The stock added roughly 14.8% over the last three months.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Patterson Companies (PDCO) Earnings Beat Estimates in Q4
Patterson Companies Inc. (PDCO - Free Report) reported fourth-quarter fiscal 2017 adjusted earnings of 69 cents per share from continuing operations, which outpaced the Zacks Consensus Estimate of 64 cents. The figure, however, came lower than the year-ago quarterly figure of 77 cents.
Net sales from continuing operations dipped 0.62% from the year-ago quarter to $1.45 billion missing the Zacks Consensus Estimate of $1.47 billion.
Stock Performance
The price performance of the stock has been unfavorable over the last three months. Patterson Companies shed 1.24%, comparing unfavorably versus the Zacks classified Medical - Dental Supplies sub-industry’s gain of almost 5.46%.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Patterson Companies, Inc. Price, Consensus and EPS Surprise | Patterson Companies, Inc. Quote
Quarter Details
Coming to the Animal Health platform (58% of total sales), sales increased almost 6.0% on a year-over-year basis to $827.5 million. Sales of Consumable grew 5.1% year over year. However, the Other services and products on this platform witnessed a 5.8% year-over-year decline in sales.
Patterson Companies’ Dental platform (42% of total sales) sales fell 8.3% year over year to $607.3 million approximately. Consumable sales at the Dental platform dropped 4.3% year over year to $339.4 million, while sales from other services and products increased by 0.2%. Sales from dental equipment and software dipped 16.9%.
Financial Condition
Cash and cash equivalents were $94.9 million as of Apr 29, 2017 compared to $137.5 million as of Apr 30, 2016. In fiscal 2017, Patterson repurchased approximately 2.9 million shares for $125.4 million. This leaves approximately 13.6 million shares for repurchase under the current authorization, which expires in Mar 2018. The company also disbursed $25.0 million in cash dividends to shareholders in the fourth quarter and $95.9 million in cash dividends to shareholders in fiscal 2017.
Outlook
Patterson Companies affirmed its adjusted earnings in the range of $2.25–$2.40 per share for fiscal 2018. GAAP earnings are expected to be in the range of $1.90 to $2.05 per diluted share.
Zacks Rank & Key Picks
Patterson Companies currently has a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector are Luminex Corp. , Inogen, Inc. (INGN - Free Report) and Edwards Lifesciences, Inc. (EW - Free Report) . Notably, Luminex and Inogen sport a Zacks Rank #1 (Strong Buy), while Edwards Lifesciences carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an expected long-term adjusted earnings growth of almost 16.3%. The stock roughly added 7.0% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 82%.
Edwards Lifesciences has an expected long-term adjusted earnings growth of almost 16% (last 3–5 years of actual earnings). The stock added roughly 14.8% over the last three months.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>